Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Accounts Payables (2016 - 2025)

Historic Accounts Payables for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $9.8 million.

  • vTv Therapeutics' Accounts Payables rose 5745.26% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 5745.26%. This contributed to the annual value of $5.0 million for FY2024, which is 5091.78% down from last year.
  • vTv Therapeutics' Accounts Payables amounted to $9.8 million in Q3 2025, which was up 5745.26% from $5.2 million recorded in Q2 2025.
  • Over the past 5 years, vTv Therapeutics' Accounts Payables peaked at $12.5 million during Q1 2022, and registered a low of $4.2 million during Q1 2025.
  • Over the past 5 years, vTv Therapeutics' median Accounts Payables value was $7.3 million (recorded in 2022), while the average stood at $7.5 million.
  • As far as peak fluctuations go, vTv Therapeutics' Accounts Payables surged by 15123.87% in 2022, and later plummeted by 5199.86% in 2025.
  • Over the past 5 years, vTv Therapeutics' Accounts Payables (Quarter) stood at $8.0 million in 2021, then dropped by 8.85% to $7.3 million in 2022, then skyrocketed by 40.05% to $10.2 million in 2023, then plummeted by 50.92% to $5.0 million in 2024, then surged by 95.01% to $9.8 million in 2025.
  • Its Accounts Payables stands at $9.8 million for Q3 2025, versus $5.2 million for Q2 2025 and $4.2 million for Q1 2025.